Web1 dag geleden · RALEIGH, N.C., April 13, 2024 /PRNewswire/ -- Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, today announced the closing... Web4 uur geleden · A small Raleigh-based startup hopes to shake up the chronic obstructive pulmonary disease (COPD) market with a treatment for an underserved target—airway mucus plugs. Aer Therapeutics closed a $36 million Series A Thursday to take its inhaled mucolytic to the clinic. The new company is a spin-out from John Fahy’s lab at UCSF.
Aer Therapeutics’s Competitors, Revenue, Number of Employees, …
Web9 uur geleden · Aer Therapeutics CEO Jim Shaffer (L) and founder John Fahy. April 13, 2024 07:00 AM EDT. Financing. Startups. Trio of VCs launches Gaelic-inspired Aer Therapeutics with $36M to prove ... WebContact Jim Shaffer, [email protected] Address 400 W North Street, Suite 112, Raleigh NC 27603 jw shelton
Aer Therapeutics raises $36m for COPD drug ThinkBusiness
WebFollowing Celgene's acquisition of Quanticel in 2015, Jim was the founding CSO of Jecure Therapeutics, which was acquired by Genentech in 2024 for its NLRP3 discovery program. Jim has contributed to the discovery of several compounds that have advanced to clinical trials including Votrient ™ (pazopanib), Tykerb ™ (lapatinib), SNX-5422, CC-90010, and … WebAer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are … WebAer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for muco-obstructive lung diseases, today announced the closing of a $36 million Series A financing. Funding was received from a syndicate of premier life science industry investors, including Canaan, OrbiMed, and Hatteras Venture Partners. jw shiep edu cn